Bioventix
BVXP · AIM · Health Care · mcap £88m · 1825.0p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 20 Apr 26 | Share Options Awarded
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces the award on 17 April 2026 of share opti |
+0.0% | |
| 30 Mar 26 | Results | Half-year Results
Unaudited Interim Results for the six months ended 31 December 2025 |
+6.9% |
| 24 Feb 26 | Board change | Appointment of Non-Executive Director
Bioventix PLC (AIM: BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, is delighted to announce the appointment of C |
+0.0% |
| 27 Oct 25 | Results | Results for the year ended 30 June 2025
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its audited results for the year ended 3 |
−15.7% |
Company filings. Not investment advice.